

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Genscript Biotech Corporation**

**金斯瑞生物科技股份有限公司\***

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock code: 1548)**

## **INSIDE INFORMATION ANNOUNCEMENT**

This announcement is made by Genscript Biotech Corporation (the “**Company**”, together with its subsidiaries, the “**Group**”) with respect to the two reports issued by Flaming Research (“**Flaming**”) (collectively, the “**Reports**”) which contain allegations against the Company, and is published by the Company pursuant to Rule 13.09 of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the “**SFO**”).

Reference is made to the announcements of the Company dated 28 September 2018 and 3 October 2018 in relation to the Reports and the Company’s refutation and/or clarification of the allegations made in the Reports, and the announcement of the Company dated 1 October 2018 in relation to the first Report and the legal actions taken and to be taken by the Company (collectively, the “**Announcements**”). Unless otherwise defined, capitalized terms used in this announcement shall have the same meanings as defined in the Announcements.

In order to protect the interest of shareholders (the “**Shareholders**”) and potential investors of the Company, the Company has submitted and reported to the Securities and Futures Commission of Hong Kong on the possible market misconduct by the relevant person(s) in relation to the Reports and requested for a thorough investigation into the matter on 12 October 2018.

The Company will update the Shareholders and potential investors as and when appropriate of any further development related to the investigation of the matter.

The Company wishes to emphasize that the business operations and financial conditions of the Company continue to remain normal and healthy. The Company has always and will continue to strive to build on its core competitiveness in order to maximize return for its Shareholders as a whole.

**Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.**

By Order of the Board  
**Genscript Biotech Corporation**  
**Dr. Zhang Fangliang**  
*Chairman and Chief Executive Officer*

Hong Kong, 12 October 2018

*As at the date of this announcement, our executive Directors are Dr. ZHANG Fangliang, Ms. WANG Ye, and Mr. MENG Jiange; our non-executive Directors are Dr. WANG Luquan and Mr. PAN Yuexin; and our independent non-executive Directors are Mr. GUO Hongxin, Mr. DAI Zumian, and Ms. ZHANG Min.*

\* *For identification purposes only*